Project Details
Description
FATE FT596 with Rituximab as Relapse Prevention in High Risk Patients after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma
| Status | Active |
|---|---|
| Effective start/end date | 5/1/20 → 4/30/26 |
Funding
- FATE THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.